Clinical and Molecular Delineation of the 17q21.31 Microdeletion Syndrome
Overview
Authors
Affiliations
Background: The chromosome 17q21.31 microdeletion syndrome is a novel genomic disorder that has originally been identified using high resolution genome analyses in patients with unexplained mental retardation.
Aim: We report the molecular and/or clinical characterisation of 22 individuals with the 17q21.31 microdeletion syndrome.
Results: We estimate the prevalence of the syndrome to be 1 in 16,000 and show that it is highly underdiagnosed. Extensive clinical examination reveals that developmental delay, hypotonia, facial dysmorphisms including a long face, a tubular or pear-shaped nose and a bulbous nasal tip, and a friendly/amiable behaviour are the most characteristic features. Other clinically important features include epilepsy, heart defects and kidney/urologic anomalies. Using high resolution oligonucleotide arrays we narrow the 17q21.31 critical region to a 424 kb genomic segment (chr17: 41046729-41470954, hg17) encompassing at least six genes, among which is the gene encoding microtubule associated protein tau (MAPT). Mutation screening of MAPT in 122 individuals with a phenotype suggestive of 17q21.31 deletion carriers, but who do not carry the recurrent deletion, failed to identify any disease associated variants. In five deletion carriers we identify a <500 bp rearrangement hotspot at the proximal breakpoint contained within an L2 LINE motif and show that in every case examined the parent originating the deletion carries a common 900 kb 17q21.31 inversion polymorphism, indicating that this inversion is a necessary factor for deletion to occur (p<10(-5)).
Conclusion: Our data establish the 17q21.31 microdeletion syndrome as a clinically and molecularly well recognisable genomic disorder.
Epilepsy, EEG and chromosomal rearrangements.
Paprocka J, Coppola A, Cuccurullo C, Stawicka E, Striano P Epilepsia Open. 2024; 9(4):1192-1232.
PMID: 38837855 PMC: 11296106. DOI: 10.1002/epi4.12951.
Unraveling the complex role of MAPT-containing H1 and H2 haplotypes in neurodegenerative diseases.
Pedicone C, Weitzman S, Renton A, Goate A Mol Neurodegener. 2024; 19(1):43.
PMID: 38812061 PMC: 11138017. DOI: 10.1186/s13024-024-00731-x.
Yoo L, Mendoza D, Richard A, Stephens J Genes (Basel). 2024; 15(5).
PMID: 38790268 PMC: 11121512. DOI: 10.3390/genes15050639.
Awamleh Z, Choufani S, Wu W, Rots D, Dingemans A, Nadif Kasri N Eur J Hum Genet. 2024; 32(3):324-332.
PMID: 38282074 PMC: 10923882. DOI: 10.1038/s41431-024-01538-6.
St John M, Van Reyk O, Koolen D, de Vries B, Amor D, Morgan A Eur J Hum Genet. 2022; 31(5):531-540.
PMID: 36529818 PMC: 10172335. DOI: 10.1038/s41431-022-01230-7.